Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oncopeptides in connection with a directed share issue (5)
Mandate

Vinge advises Oncopeptides in connection with a directed share issue

July 15, 2022 Banking and Finance Capital Markets and Public M&A

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 435,6 million, before issue costs. The price per share in the share issue corresponds to the closing price on Nasdaq Stockholm the day of the share issue.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors.

Oncopeptides is a biotech company focused on research and development of pharmaceuticals for difficult-to-treat haematological diseases. The Company uses its proprietary PDC platform to develop peptide-drug conjugated compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström (capital markets), and Louise Brorsson Salomon, Arvid Weimers and Kamyar Najmi (financing).

Related

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025

Vinge advises Advania in connection with the acquisition of atNorth HPC AB

Vinge has advised Advania, one of the leading IT companies in the Nordic region, in connection with the acquisition of atNorth HPC AB. The acquisition strengthens Advania's presence within high-performance computing (HPC).
October 03, 2025